
Abstract Background Major depressive disorder (MDD) is associated with increased stroke risk and can be conceptualized in Traditional Chinese Medicine (TCM) as emotional constraint or “Qi Stagnation” that may contribute to “Blood Stasis.” However, the country-level ecological relationship between stroke burden and MDD prevalence remains unclear, and high-stroke settings may have under-recognized MDD because of differences in data availability, diagnostic practices, mental health services, and cultural symptom expression. This study quantifies this ecological association and interprets it through an Integrated Medicine framework. Methods Using Global Burden of Disease (GBD) 2023 data, we analyzed age-standardized stroke Disability-Adjusted Life Year (DALY) rates for all stroke and age-standardized prevalence rates for the GBD cause category of MDD across 204 countries and territories from 1990 to 2023. An exploratory Diagnostic Gap Score (ZStroke—ZMDD) was developed to identify countries and territories with disproportionate stroke burden relative to reported MDD prevalence. Results A negative ecological correlation emerged globally and strengthened over time ( r = −0.059 in 1990 versus r = −0.218 in 2023, P = 0.002). The highest stroke burden quartile (Q4) reported lower MDD prevalence (2639.9/100 000) than the lowest quartile (3067.0/100 000; mean difference 427.1/100 000, 95% CI: 121.52 to 732.58), despite an 8.3% increase in stroke burden in Q4. The score identified clusters with disproportionate stroke burden relative to MDD prevalence in Eastern Europe, Southeast Asia, and Pacific Island settings. Conclusions Low reported MDD prevalence in high-stroke countries and territories suggests a potential diagnostic, reporting, or data-quality mismatch rather than biological protection. These ecological findings do not prove that undiagnosed MDD causes stroke burden, but they support culturally adapted mental health screening in primary care, stroke-prevention clinics, and community health settings, with referral pathways for those who screen positive.
Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the most common form of dementia. Women are differentially affected by AD, and several sex-specific mechanisms have been explored, including hormonal differences (eg, estrogen). Glucagon-like peptide-1 (GLP-1R) are located in brain regions implicated in the pathogenesis of AD and shows preliminary evidence of modulating sex-specific pathways that may underlie differential disease risk and progression. Herein, we synthesize the extant literature on the mechanisms of GLP-1 in neurobiological systems relevant to AD pathology. Metabolic signalling (eg, GLP-1, insulin) intersects with known sex-specific pathways hypothesized to subserve AD progression in women. The preceding effects may be attributable to the disruption of estrogen signalling during the postmenopausal period, which impairs hippocampal insulin receptor function and exacerbates mitochondrial dysfunction. In addition, these mechanisms provide an explanation for AD comorbidities (eg, type 2 diabetes mellitus [T2DM]). The multidimensional effects demonstrated in GLP-1 paradigms provide a compelling rationale for further investigation of the role of metabolic signalling on sex-specific alterations in AD. Evidence across preclinical and early clinical studies suggests that GLP-1RAs may differentially influence neurobiological pathways implicated in AD pathogenesis, particularly those that interact with hormonal and metabolic systems.
Abstract Our understanding of functional neurological symptom disorder (FND) has evolved more quickly than dissemination of our progressed knowledge. Healthcare providers remain suboptimally educated about and trained in FND-informed care. As a result, patients continue to have harmful interactions with the healthcare system around FND, often beginning with poorly established and delivered diagnosis and uninformed or otherwise lacking treatment planning. This results in iatrogenic harm to patients and misuse of healthcare resources. Appreciating this, providers repeatedly request guidance on FND-informed diagnosis and treatment. This article serves to provide guidance on FND diagnosis and treatment planning for healthcare providers and patients.
Abstract Background Social anxiety disorder (SAD) is a common and debilitating condition marked by intense fear of negative evaluation in social situations. It often co-occurs with other psychiatric disorders, and in particular Autism Spectrum Disorder (ASD). The exact cause of SAD is unclear, though biological, environmental, and genetic factors are believed to contribute. Recent research highlights the involvement of neuropeptides, neurohormones, and immune system components in SAD development, suggesting complex interactions between psychological and biological factors, with a growing focus on inflammation’s role. This study aimed to investigate potential biochemical correlates of SAD in individuals with ASD, their first-degree relatives (BAP group), and healthy controls (HCs), focusing on inflammatory markers, neuropeptides, and growth factors. Methods Twenty-four adults with ASD, their relatives, and HCs, for a total of 72 participants, were assessed. Biochemical parameters were analyzed using enzyme-linked immunosorbent assays (ELISA), and social anxiety symptoms were evaluated via the Social Phobia Spectrum—Self Report (SHY-SR) questionnaire. Results Individuals with ASD exhibited significantly higher SHY-SR scores compared to the BAP and HCs. Subjects in the ASD group tended to make greater use of anxiolytics in order to improve their social interaction skills. Additionally, a specific pattern of correlation and association was found between biochemical variables and specific SAD symptoms, suggesting a potential role of inflammatory pathways in SAD pathophysiology. Conclusions Our results confirm the presence of greater social phobic symptoms in subjects with ASD, and support the hypothesis of a role of the inflammatory cascade in the maintenance of the disorder.
Abstract Social anxiety disorder (SAD) is a common and often chronic psychiatric illness characterized by persistent fear of social or performance situations and associated functional impairment and avoidance. Although multiple pharmacologic treatments have been studied, questions remain regarding optimal sequencing of therapies, long-term treatment strategies, and the management of partial or treatment-resistant illness. This narrative review synthesizes the evidence for pharmacologic treatments for SAD across medication classes, including antidepressants, benzodiazepines, monoamine oxidase inhibitors, GABA-related agents, second-generation antipsychotics, and emerging interventions. It also examines as-needed (PRN) interventions and steroid-based approaches, deprescribing and proposes a definition of treatment-resistant SAD. Randomized controlled trials, open-label studies, and guideline recommendations were reviewed to provide a framework for pharmacologic decision-making. Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) remain the best-supported first-line pharmacotherapies for SAD. Evidence supports switching within or across antidepressant classes and integrating pharmacotherapy with behavioral interventions in patients with incomplete response. Additional treatments, including benzodiazepines, monoamine oxidase inhibitors, pregabalin, and selected augmentation strategies, may be considered for patients with persistent symptoms, although the evidence base is more limited. Data regarding long-term outcomes and treatment-resistant populations remain relatively sparse. While serotonergic antidepressants remain the cornerstone of treatment, optimal management requires individualized sequencing of therapies, integration with behavioral interventions, and consideration of alternative mechanisms in patients with incomplete response. Future studies should prioritize comparative effectiveness, long-term outcomes, and interventions for treatment-resistant SAD.